Wedbush Reiterates Outperform on Travere Therapeutics, Maintains $13 Price Target
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst Laura Chico has reiterated an Outperform rating on Travere Therapeutics (NASDAQ:TVTX) and maintained a $13 price target.
February 16, 2024 | 1:57 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Wedbush analyst Laura Chico reaffirmed an Outperform rating on Travere Therapeutics with a $13 price target.
The reiteration of an Outperform rating and maintenance of a $13 price target by a reputable analyst could positively influence investor sentiment towards TVTX, potentially driving its stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100